INO vs DVAX

For growth investors, Dynavax Technologies Corporation (DVAX) is the stronger pick with 19.

4% revenue growth year-over-year, versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). Dynavax Technologies Corporation (DVAX) offers the better valuation at 77. 5x trailing P/E (31. 6x forward), making it the more compelling value choice. Analysts rate Inovio Pharmaceuticals, Inc. (INO) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Dynavax Technologies Corporation (DVAX) delivered a total return of +58.

0%, compared to -98. 3% for Inovio Pharmaceuticals, Inc. (INO). Over 10 years, the gap is even starker: DVAX returned +2. 9% versus INO's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Dynavax Technologies Corporation (DVAX) is the lower-risk stock at 0.

75β versus Inovio Pharmaceuticals, Inc. 's 1. 31β — meaning INO is approximately 75% more volatile than DVAX relative to the S&P 500. On balance sheet safety, Inovio Pharmaceuticals, Inc. (INO) carries a lower debt/equity ratio of 39% versus 43% for Dynavax Technologies Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Dynavax Technologies Corporation (DVAX) is pulling ahead at 19.

4% versus -100. 0% for Inovio Pharmaceuticals, Inc. (INO). On earnings-per-share growth, the picture is similar: Dynavax Technologies Corporation grew EPS 503. 2% year-over-year, compared to 54. 2% for Inovio Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Dynavax Technologies Corporation (DVAX) is the more profitable company, earning 9.

9% net margin versus 0. 0% for Inovio Pharmaceuticals, Inc. — meaning it keeps 9. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INO leads at 0. 0% versus -1. 5% for DVAX. At the gross margin level — before operating expenses — DVAX leads at 82. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INO: 338.

0% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Dynavax Technologies Corporation (DVAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

75)). Both have compounded well over 10 years (DVAX: +2. 9%, INO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INO is a small-cap quality compounder stock; DVAX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.